Abstract 2602: The nonclinical toxicology profile of pacritinib, a JAK2FLT3 inhibitor with no dose-limiting clinical myelosuppression

Pacritinib is an orally active kinase inhibitor being developed for the treatment of myelofibrosis (MF). Pacritinib is a particularly potent inhibitor of wild-type and mutant isoforms of JAK2 and FLT3 (IC50 values < 15 nM), and it does not suppress JAK1 at clinically relevant concentrations. Addi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.2602-2602
Hauptverfasser:	Watson, Rebecca, Al-Fayoumi, Suliman
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!